Skip to main content

Risk for Periprosthetic Joint Infections Increased With Chemo After Arthroplasty

Medically reviewed by Carmen Pope, BPharm. Last updated on May 24, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 24, 2024 -- Postoperative chemotherapy is associated with an increased incidence of periprosthetic joint infections (PJI) among patients with total joint arthroplasties, according to a study published online May 2 in the Archives of Orthopaedic and Trauma Surgery.

Amir Human Hoveidaei, M.D., from the Rubin Institute for Advanced Orthopedics at the Sinai Hospital of Baltimore, and colleagues examined whether chemotherapy increases PJI rates in patients who received postarthroplasty chemotherapy within one year of surgery. Patients in a matched control group did not receive postarthroplasty chemotherapy. Data were included from 8,558 total knee arthroplasty (TKA) patients; 6,707 total hip arthroplasty (THA) patients; and 1,761 total shoulder arthroplasty (TSA) patients.

The researchers found that PJI rates were significantly higher in the chemotherapy group at two, three, and four years for TKA (odds ratios, 1.59, 1.57, and 1.40, respectively) and at two, three, and four years for THA (odds ratios, 2.27, 2.32, and 2.25, respectively). After four years, TSA patients had a significant increase in PJI rates (odds ratio, 2.20).

"Postoperative chemotherapy agents may potentiate the development of PJI in patients who have undergone knee, hip, or shoulder joint arthroplasty. Future prospective studies focusing on this potential correlation would be crucial, so that essential and preventive measures can be taken into account," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

Nudging Both Clinicians, Patients May Increase Serious Illness Conversations

TUESDAY, July 2, 2024 -- Combining clinician- and patient-directed nudges may help to promote serious illness conversations (SICs) in cancer care, according to a study published...

Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer

TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...

Racial Differences Seen in Financial Hardship Among Older Cancer Survivors

MONDAY, July 1, 2024 -- Income and area-level disadvantage are the largest contributors to racial differences in financial hardship among older U.S. adults with cancer, according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.